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Accepted 16 October 2019; Published online 19 October 2019AbstractObjective: The objective of this study was to establish thresholds for clinical importance (TCIs) for the five functioning and nine symp-
tom scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
Study Design and Setting: In this diagnostic study, cancer patients with mixed diagnoses and treatments completed the EORTC QLQ-
C30 and anchored the questions in each domain in terms of their clinical importance. The anchor questions, concerned limitations in daily
life, need for help/care, and the worries of the patient and his/her partner/family. These questions allowed categorizing patients into whether
they exhibited a clinically important symptom/functional impairment for each scale and performing a receiver operating characteristic
curve analysis to establish TCIs.
Results: Data from 498 patients from six European countries (mean age 60.4 years, 55.2% women) were analyzed. For the TCIs gener-
ated using the patient questionnaire data, the EORTC QLQ-C30 scales showed sensitivity values between 0.71 and 0.97 and specificity
values between 0.62 and 0.92 (area under the curve above 0.80 for all scales).
Conclusion: This EORTC Quality of Life Group study provides TCIs for the functioning and symptom scales of the EORTC QLQ-
C30. These TCIs can increase the interpretability of the questionnaire results and foster its use in daily clinical practice and in clinical
research.  2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
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The European Organisation for Research and Treatment
of Cancer Quality of Life Questionnaire Core 30 (EORTC
QLQ-C30) [1] is one of the most widely used patient-
reported outcome (PRO) questionnaires for assessing qual-
ity of life (QOL), functional health, and symptom burden in
patients with cancer worldwide [2]. Historically, it has
served as an outcome measure in cancer clinical trials,ess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 In our study, we have developed thresholds for
clinical importance for the EORTC QLQ-C30,
one of the most widely used questionnaires in can-
cer research, that assesses functional health, symp-
toms and global quality of life. We have found that
the questionnaire provides excellent diagnostic ac-
curacy for identification of clinically important
symptoms and functional health impairments.
What this adds to what was known?
 These thresholds are the first that rely on criteria
developed systematically including the views of
both patients with cancer and health professionals.
What is the implication and what should change
now?
 Interpretation of scores from the EORTC QLQ-C30
which are given on a 0-100 metric can be chal-
lenging. The thresholds facilitate interpretation of
such scores and can be used e.g., for symptom
screening in daily practice, or for calculating symp-
tom prevalence rates from the EORTC QLQ-C30.
but in recent years, it is increasingly being used for patient
monitoring in daily clinical practice [3].
However, interpreting the scores from this and other
PRO questionnaires can be challenging for clinicians and
researchers. A number of approaches have been used to
facilitate interpretation of these scores, usually by making
their meaning more tangible. Most efforts have focused
on defining minimal important differences, which offer a
reference for interpreting the clinical importance of differ-
ences in scores between groups or changes in scores over
time [4e6]. Unfortunately, these approaches do not aid in
the interpretation of absolute scores obtained from an indi-
vidual patient at a single point in time. For such absolute
scores, thresholds are necessary for converting metric
PRO scores into symptom prevalence rates or to screen
for clinically important symptoms and functional impair-
ments in daily practice.
Previous studies have used different methodological ap-
proaches to develop thresholds that aid in the interpretation
of absolute scores, including cutoff scores based on the
wording of the response categories [7,8], identifying score
distributions in specific patient populations [9,10], or refer-
ring to external criteria such as need for care [11e13]. How-
ever, the criteria for establishing thresholds in these studies
were either created ad hoc or defined by experts only; in
other words, they were not developed systematically
including the views of both patient and health professionals.
2 J.M. Giesinger et al. / Journal ofTo meet the need for well-defined, valid thresholds, the
EORTC Quality of Life Group initiated a project to develop
thresholds for clinical importance (TCIs) for the absolute
scores on the QLQ-C30 based on external criteria reflecting
the clinical importance of a health problem. Clinical impor-
tance is defined as any aspect of a health problem that
makes it relevant for the clinical encounter. The specific
external criteria (limitations in daily living, perceived need
for treatment or care, and disease- or treatment-related
worry) were established in the first part of the project,
which included a Europe-wide mixed methods study of pa-
tients with cancer and health professionals [14].
Based on this groundwork, we sought to develop TCIs
for the five functioning and nine symptom scales of the
QLQ-C30. We expect that these TCIs will help improve
interpretation of scores for the QLQ-C30 in both daily clin-
ical practice and in research.2. Methods
2.1. Sample
In this prospective study, we recruited a heterogeneous
sample of patients with cancer from Austria, Italy, the
Netherlands, Poland, Spain, and the United Kingdom. There
was no restriction placed on cancer diagnosis, type of treat-
ment or treatment status (on- or off-treatment), but patients
were excluded if they had serious cognitive impairment that
would prohibit them from completing questionnaires. For
participation, patients had to be aged 18 years or older,
speak the primary language of their country of residence,
and provide written informed consent. Patients were as-
sessed at a single time point with the QLQ-C30 and a ques-
tionnaire with anchor items on clinical importance.
For data collection, we used the Computer-based Health
Evaluation System [15], which allows participants to com-
plete case report forms and questionnaires electronically.
Ethical approval was obtained from the local ethics com-
mittees according to national regulations.
2.2. The European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire
Core 30
The QLQ-C30 [1] comprises 30 items that can be sum-
marized in 15 scales: Physical Functioning (PF), Role
Functioning (RF), Social Functioning (SF), Emotional
Functioning (EF), Cognitive Functioning (CF), Global
QOL (QL), Fatigue (FA), Pain (PA), Nausea/Vomiting
(NV), Appetite Loss (AP), Dyspnea (DY), Sleep Distur-
bances (SL), Diarrhea (DI), Constipation (CO), and Finan-
cial Impact of Disease (FI). For all scales, item scores are
summed and linearly transformed into a scale ranging from
0 to 100. Higher scores on the functioning scales indicate
higher levels of functioning, whereas higher scores on the
symptom scales represent more symptom burden.
3J.M. Giesinger et al. / Journal of Clinical Epidemiology 118 (2020) 1e82.3. Assessment of clinical importance
In a previous mixed methods study [14], we identified
various aspects that make a symptom or function clinically
importantdthat is, deserving attention and discussion dur-
ing the clinical encounter. The aspects most frequently
mentioned by patients and health care providers were lim-
itations in everyday life, the problem indicates/causes other
problems, the emotional impact of a problem on the patient
and/or family/partner, duration or frequency, change from
normal, and the need for treatment/care.
Drawing on these aspects, we defined anchor items to be
used as external criteria for developing TCIs for all QLQ-
C30 scales (with the exception of the QL scale). The anchor
items were defined via a consensus discussion within an
EORTC Quality of Life Group meeting consisting of 23
members of different professional backgrounds (e.g.,
oncology, surgery, psychology, nursing, statistics). Before
the meeting, a report was circulated among group members
summarizing the findings of the aforementioned mixed
methods study and detailing a number of considerations
on the various aspects of clinical importance. These consid-
erations helped to guide definition of the anchor items.
Most importantly, we decided to use the same set of anchor
items (with domain-specific wording) for all scales to
ensure that the meaning of the TCIs was consistent across
domains. For this reason, we did not consider associations
between particular domains as possible anchors. We also
excluded the ‘‘duration or frequency’’ and ‘‘change from
normal’’ aspects because the QLQ-C30 measures symptom
severity, which is conceptually different from these aspects.
We created the following anchor items (with domain-
specific wording) to assess clinical importance separately
for each domain:
 Limitations: ‘‘Has your SYMPTOM/PROBLEM
limited your daily life?’’
 Need for help: ‘‘Have you needed any help or care
because of your SYMPTOM/PROBLEM?’’
 Worries: ‘‘Has your SYMPTOM/PROBLEM caused
you or your family/partner to worry?’’
Three domains (RF, SF, and PA) of the QLQ-C30 ask
about both severity and interference in daily life; thus, we
did not include the limitations anchor for these domains.
In line with a previous pilot study [16], the standard
QLQ-C30 response format was used for the anchor items
(4-point Likert scale with responses of not at all, a little,
quite a bit, and very much). A patient was categorized as
a positive case (i.e., as having a clinically important prob-
lem/symptom) if (s)he selected ‘‘quite a bit’’ or ‘‘very
much’’ on at least one of the anchor items.2.4. Statistical analysis
Descriptive statistics for the QLQ-C30 were calculated
separately for positive and negative cases. We alsocalculated group differences in absolute scores and the cor-
responding effect sizes (Cohen’s d statistic based on the
pooled standard deviation from positive and negative
cases). To evaluate the consistency of the anchor items,
we calculated the ranges and medians of the Spearman rank
correlation coefficients across the QLQ-C30 scales.
We defined the TCIs using receiver operating character-
istic (ROC) analysis, setting the QLQ-C30 scales as predic-
tors and using the binary criterion of clinical importance for
definition of positive/negative cases (e.g., a patient was a
‘‘positive’’ for pain if (s)he answered quite a bit, or very
much to at least one of the three criteria related to pain).
For each scale, we selected the threshold with the highest
Youden’s J statistic [17] (the sum of sensitivity and speci-
ficity minus one), or if the Youden’s J of two adjacent
thresholds differed by less than 0.05, we selected the
threshold with higher sensitivity. If these thresholds had a
sensitivity below 0.70, we selected the closest threshold
providing a sensitivity above this value.
The areas under the curve (AUC) were calculated to
determine the diagnostic accuracy of each scaledthat is,
the ability of each scale to discriminate between negative
and positive cases. As per Hosmer and Lemeshow [18],
AUCs of 0.70-0.80 indicated acceptable discrimination
and AUCs above 0.80 indicated excellent discrimination.
Sensitivity analyses were conducted to investigate the
variability in TCIs and diagnostic accuracy across 14 pa-
tient groups, defined by age (below/above 60y), sex, treat-
ment intention (curative/palliative), treatment status (on/
off), comorbidity (no/yes), and European region (Western
Europe [Austria and the Netherlands], Southern Europe
[Italy and Spain], Eastern Europe [Poland], and the UK).
To evaluate diagnostic accuracy, we calculated group-
specific AUCs for each QLQ-C30 scale. Invariance in TCIs
was investigated separately for each scale using multivar-
iate binary logistic regression models with the above
grouping variables and the QLQ-C30 scale as independent
variables, and the binary criterion for clinical importance as
the dependent variable. In such models, a statistically sig-
nificant (P ! 0.01) grouping variable indicates that TCIs
are different between groups. For significant grouping vari-
ables, we determined the TCIs for each subgroup using the
aforementioned decision rule based on Youden’s J and
compared these TCIs with those of the total sample.
An a priori power analysis indicated that 500 patients
(assuming 33% positive cases) would provide a power of
0.80 to demonstrate (with a two-sided alpha of 0.05) that
the AUC is above 0.80 if the observed AUC is 0.865.
The power analysis was conducted with PASS 11.0 [19].3. Results
3.1. Patient characteristics
Between November 2016 and November 2018, we re-
cruited 502 patients at eight centers in the six countries.
Table 1. Descriptive statistics for sociodemographic and clinical
variables (n 5 498)
Variable Mean (SD) Range
Age 60.4 (12.7) 19-87
N %
Sex Women 272 55.2
Men 221 44.8
Missing data 5
Diagnosis Breast cancer 117 23.6
Hematological malignancy 66 13.3
Lung cancer 49 9.9
Prostate cancer 48 9.7
Colorectal cancer 42 8.5
Head and neck cancer 39 7.9
Lymphoma 37 7.5
Gynecologic cancer 29 5.9
Stomach cancer 12 2.4
Brain cancer 10 2.0
Other 46 9.3
Missing data 3
UICC stagea I 61 16.1
II 100 26.4
III 79 20.8
IV 139 36.7
Missing data 16
Comorbidity No 272 59.0
Yes 189 41.0
Missing data 37
Treatment
intention
Curative 282 60.6
Palliative 183 39.4
Missing data 33
Current
treatment
No current treatment 115 23.3
Current treatment 379 76.7
Surgeryb 135 35.6
Chemotherapyb 232 61.2
Radiotherapyb 127 33.5
Otherb 81 21.4
Missing data 4
Abbreviation: UICC, Union for International Cancer Control.
a Only reported for patients with solid tumors.
b More than one treatment is possible, so the percentages for the
treatment modalities do not sum up to 100%.
Table 2. Number of patients with clinically important problems/
symptoms (positive cases) and those without (negative cases) for
each EORTC QLQ-C30 scale
EORTC QLQ-C30 scale Cases N %
Physical Functioning (PF) Positive 270 54.5
Negative 225 45.5
Role Functioning (RF)a Positive 122 24.6
Negative 373 75.4
Social Functioning (SF)a Positive 92 18.5
Negative 404 81.5
Emotional Functioning (EF) Positive 139 28.0
Negative 357 72.0
Cognitive Functioning (CF) Positive 57 11.5
Negative 439 88.5
Fatigue (FA) Positive 176 35.5
Negative 320 64.5
Pain (PA)a Positive 89 18.0
Negative 405 82.0
Nausea/Vomiting (NV) Positive 51 10.3
Negative 443 89.7
Sleep Disturbances (SL) Positive 95 19.2
Negative 399 80.8
Dyspnea (DY) Positive 90 18.2
Negative 404 81.8
Appetite Loss (AP) Positive 54 10.9
Negative 440 89.1
Constipation (CO) Positive 49 9.9
Negative 444 90.1
Diarrhea (DI) Positive 41 8.3
Negative 453 91.7
Financial Impact (FI) Positive 70 14.2
Negative 423 85.8
Cases were defined using all external criteria (worries of patient/
partner/family, limitations in daily life, and need for help/care).
a Please note that the anchor item for limitations in daily life was
not used for Role Functioning, Social Functioning, and Pain because
these scales already cover such limitations.
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were excluded from further analysis. The remaining 498
patients had a mean age of 60.4 years (SD 5 12.7) and
55.2% were women. The most frequent diagnoses were
breast cancer (23.6%), hematological malignancies
(13.3%), and lung cancer (9.9%). Most (76.7%) of patients
were receiving treatment during the assessment, and 60.6%were receiving treatment with curative intention. Comorbid
conditions were present in 41.0% of the patients. Further
details are reported in Table 1.3.2. Thresholds for clinical importance
Looking at the internal correlation between anchors, the
correlations between the limitations and the need for help
anchors ranged from 0.53 (SL) to 0.75 (PF) (me-
dian 5 0.58), correlations between the worry and limita-
tions anchors ranged from 0.47 (CO) to 0.64 (EF)
(median 5 0.56), and those between worry and need for
help ranged from 0.46 (PF) to 0.70 (SF) (median 5 0.65).
Applying our binary criterion for clinical importance,
the proportion of positive cases ranged from 8.3% (DI) to
Table 3. Comparison of EORTC QLQ-C30 scores in patients with clinically important problems/symptoms (positive cases) and those without
(negative cases)
EORTC QLQ-C30 scale
Negative cases Positive cases
Difference Effect sizeaMean SD Mean SD
Functioning scales
Physical Functioning (PF) 88.0 12.3 61.8 24.8 26.2 1.30
Role Functioning (RF) 75.6 24.8 32.5 25.3 43.1 1.73
Social Functioning (SF) 75.5 24.0 37.5 30.5 38.0 1.50
Emotional Functioning (EF) 83.3 15.0 52.4 22.5 30.9 1.77
Cognitive Functioning (CF) 84.4 19.0 54.8 27.1 29.6 1.48
Symptom scales
Fatigue (FA) 25.8 18.2 66.7 22.2 40.9 2.08
Pain (PA) 15.0 20.2 62.5 27.0 47.6 2.20
Nausea/Vomiting (NV) 5.8 12.1 46.0 33.4 40.2 2.58
Sleep Disturbances (SL) 24.0 25.5 69.5 27.4 45.5 1.76
Dyspnea (DY) 14.8 21.0 56.7 25.2 41.9 1.92
Appetite Loss (AP) 16.5 23.3 64.2 25.8 47.7 2.02
Constipation (CO) 14.2 23.2 64.6 34.3 50.4 2.06
Diarrhea (DI) 10.0 20.5 50.4 30.8 40.4 1.88
Financial Impact (FI) 8.0 17.7 61.9 32.2 53.9 2.65
a Cohen’s d based on pooled standard deviation.
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between negative and positive cases (in terms of effect size)
were largest for FI (Cohen’s d 5 2.65) and NV (d 5 2.58)
and smallest for PF (d 5 1.30) and CF (d 5 1.48). The de-
tails are reported in Tables 2 and 3.
All scales had AUCs above 0.80, with the lower limits of
their 95% confidence intervals being above 0.75. The high-
est AUCs were observed for FA (0.92) and FI (0.91) and the
lowest for CF (0.81) and PF (0.82). The TCIs given inTable 4. Results of the receiver operating characteristic (ROC) analysis and
QLQ-C30 scale TCI Sensitivity 95% CI
Functioning scales
Physical Functioning 83 0.79 0.74-0.84
Role Functioning 58 0.82 0.75-0.89
Social Functioning 58 0.71 0.62-0.81
Emotional Functioning 71 0.80 0.73-0.86
Cognitive Functioning 75 0.77 0.66-0.88
Symptom scales
Fatigue 39 0.89 0.85-0.94
Pain 25 0.92 0.87-0.98
Nausea/Vomiting 8 0.86 0.76-0.96
Sleep Disturbances 50 0.79 0.71-0.87
Dyspnea 17 0.97 0.93-1.00
Appetite Loss 50 0.78 0.67-0.89
Constipation 50 0.73 0.61-0.86
Diarrhea 17 0.88 0.78-0.98
Financial Impact 17 0.91 0.85-0.98
Abbreviations: TCI, threshold for clinical importance; AUC, area under c
Please note that for the functioning scales, scoring below the TCI indic
scores above the TCI indicate such a problem. TCIs are between values thaTable 4 and Figure 1 had sensitivities ranging from 0.71
(SF) to 0.97 (DY), and specificities ranging from 0.62
(DY) to 0.92 (CO).3.3. Sensitivity analysis
Estimating the diagnostic accuracy of each of the 14
QLQ-C30 scales within the 14 patient groups all 196 AUCs
were 0.70 (acceptable discrimination), and 178 were atthresholds for clinical importance
Specificity 95% CI AUC 95% CI
0.70 0.64-0.76 0.82 0.78-0.85
0.77 0.73-0.82 0.87 0.84-0.91
0.77 0.73-0.81 0.82 0.77-0.87
0.76 0.72-0.81 0.87 0.84-0.91
0.73 0.68-0.77 0.81 0.75-0.88
0.82 0.77-0.86 0.92 0.89-0.94
0.71 0.66-0.75 0.90 0.87-0.94
0.75 0.71-0.79 0.87 0.81-0.93
0.84 0.81-0.88 0.87 0.82-0.91
0.62 0.58-0.67 0.88 0.84-0.92
0.90 0.87-0.93 0.89 0.84-0.94
0.92 0.89-0.94 0.86 0.79-0.92
0.77 0.74-0.81 0.85 0.79-0.92
0.81 0.77-0.84 0.91 0.86-0.95
urve; CI, confidence interval.
ates a clinically important problem, whereas for the symptom scales,
t individual patients can obtain on the QLQ-C30 scales [20].
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EORTC QLQ-C30 Thresholds for Clinical Importance (TCIs)
Fig. 1. Thresholds for clinical importance (TCIs) for the functioning and symptom scales of the EORTC QLQ-C30. TCIs are shown inside the bars.
Patient scores in the orange range of the bar (i.e., below the TCI for functioning scales, or above the TCI for symptom scales) indicate clinically
important problems or symptoms. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
Core 30. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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were for CF (0.70) and CO (0.73) in Southern Europe, PF
in Western (0.74) and Eastern (0.76) Europe, and CF (0.76)
among patients on-treatment.
The sensitivity analyses of the robustness of TCIs across
patient groups indicated that only 5 of the 196 comparisons
resulted in group-specific TCIs differing from the total
sample TCIs. Specifically, for SF, a TCI of 42 provided
higher sensitivity and specificity among patients below
60 years of age (sensitivity 5 0.74, specificity 5 0.87)
and among patients from the UK (sensitivity 5 0.82, spec-
ificity 5 0.82) and Eastern Europe (sensitivity 5 0.68,
specificity 5 0.83). For PA, a TCI of 42 was more discrim-
inative among patients with comorbidities (sensi-
tivity 5 0.78, specificity 5 0.90) and patients from
Eastern Europe (sensitivity 5 0.83, specificity 5 0.97).
Finally, for CO, the optimal TCI in Southern Europe was
17 (sensitivity 5 0.64, specificity 5 0.75).4. Discussion
In this study, we established TCIs for all QLQ-C30 func-
tioning and symptom scales and demonstrated their high
diagnostic accuracy in identifying functional impairments
and symptoms that limit a patient’s daily life, cause worry
to the patient and/or his/her partner or family, or require
help or care. These thresholds will facilitate the use of
the QLQ-C30 in daily clinical practice and in research, asthey allow for the conversion of absolute scores to preva-
lence rates, thereby making QLQ-C30 data more accessible
to clinicians and researchers who find it challenging to
interpret metric data on a 0-100 scale. The sensitivity anal-
ysis investigating the robustness of TCIs and diagnostic ac-
curacy indicated that invariance can be assumed for the vast
majority of patient groups, with only the language/country
being a possible minor source of variability.
The robustness of the TCIs developed in this study is
further supported by our previous study [16], wherein we
developed thresholds for four QLQ-C30 scales (PF, EF,
FA, PA) using three anchor items based on expert opinions
(burden, limitations in daily activities, and need for help).
Despite rather different anchor items, the established TCIs
were identical for all four domains in that independent sam-
ple. As such, minor variations in external criteria might not
have a substantial impact on TCIs.
Other studies have attempted to define thresholds for the
QLQ-C30 using ad hoc criteria. Hickmann et al. [11] devel-
oped thresholds for six functioning and symptom domains
using distress and supportive care needs separately as criteria.
For the latter criterion, Hickmann et al. reported the same
thresholds for RF, CF, and SF as in our study, whereas thresh-
olds for PF and FAwere higher. As for supportive care needs,
the same thresholds were found for RF, EF, and SF, whereas
the PF and FA thresholds indicated higher severity than in our
study. Snyder et al. [12] reported thresholds for PF, RF, EF,
QL, PA, and FA related to supportive care needs in two
7J.M. Giesinger et al. / Journal of Clinical Epidemiology 118 (2020) 1e8separate samples that reflected similar or lower severity
levels as compared with our results.
The QLQ-C30’s coverage of important domains of func-
tional health and key cancer symptoms [21], coupled with
these TCIs, makes it especially suitable for symptom
screening in daily clinical practice. The TCIs can also be
integrated into electronic PRO data collection software to
enable color-coding of graphical PRO result presentation
[3], which is frequently used in such software to mark
scores that require clinicians’ attention.
In a research context, TCIs may aid in the interpretation
of group-level data and allow for the calculation of preva-
lence rates. However, we should note that statistical anal-
ysis should not rely on these dichotomized scores because
of their more limited statistical power [22] and ability to
detect change over time.
A limitation of our study is that the various aspects of
clinical importance were premised on the fact that clinical
importance is related to the relevance of a symptom or
problem to patienteclinician communication in clinical en-
counters. Although we believe this assumption to be valid,
there might be other definitions of clinical importance
linked to prognostic endpoints. Nevertheless, to the best
of our knowledge, this is the first study defining clinical
importance including systematically the perspectives of pa-
tients and health professionals.
In conclusion, this EORTC Quality of Life Group study
has successfully defined TCIs for all functioning and symp-
toms scales of the QLQ-C30, thereby facilitating interpreta-
tion of the PRO scores derived from this measure. The
thresholds might help make the QLQ-C30 scores more
accessible and further increase the questionnaire’s applica-
tion in daily clinical practice and research.CRediT authorship contribution statement
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